Advertisement
ILMN vs PACB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Hold and PACB is a Hold.
ILMN's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for ILMN moved into oversold territory on November 03, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 204 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ILMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ILMN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 18 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ILMN as a result. In 71 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 45 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
ILMN moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for ILMN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.674) is normal, around the industry mean (65.986). P/E Ratio (44.195) is within average values for comparable stocks, (3.066). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Aroon Indicator for PACB shows an upward move is likely
PACB's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 138 similar instances where the Aroon Indicator showed a similar pattern. In 121 of the 138 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PACB as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for PACB just turned positive on October 28, 2026. Looking at past instances where PACB's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +18.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 224 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for PACB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 29 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where PACB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PACB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-22.835) is slightly lower than the industry average of (4.170). P/E Ratio (-5.810) is within average values for comparable stocks, (1.500). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ILMN | PACB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 31 | 100 | |
PRICE GROWTH RATING 1..100 | 39 | 38 | |
P/E GROWTH RATING 1..100 | 8 | 96 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ILMN's Valuation (83) in the Biotechnology industry is in the same range as PACB (98). This means that ILMN’s stock grew similarly to PACB’s over the last 12 months.
ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PACB (100). This means that ILMN’s stock grew similarly to PACB’s over the last 12 months.
ILMN's SMR Rating (31) in the Biotechnology industry is significantly better than the same rating for PACB (100). This means that ILMN’s stock grew significantly faster than PACB’s over the last 12 months.
PACB's Price Growth Rating (38) in the Biotechnology industry is in the same range as ILMN (39). This means that PACB’s stock grew similarly to ILMN’s over the last 12 months.
ILMN's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for PACB (96). This means that ILMN’s stock grew significantly faster than PACB’s over the last 12 months.
| ILMN | PACB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 69% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 88% |
| Advances ODDS (%) | 7 days ago 75% | 7 days ago 85% |
| Declines ODDS (%) | 3 days ago 77% | 3 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ILMN’s FA Score shows that 2 FA rating(s) are green while PACB’s FA Score has 0 green FA rating(s).
- ILMN’s FA Score: 2 green, 3 red.
- PACB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ILMN’s TA Score shows that 3 TA indicator(s) are bullish while PACB’s TA Score has 5 bullish TA indicator(s).
- ILMN’s TA Score: 3 bullish, 6 bearish.
- PACB’s TA Score: 5 bullish, 4 bearish.
Price Growth
ILMN (@Medical Specialties) experienced а -14.76% price change this week, while PACB (@Medical/Nursing Services) price change was -0.41% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.30%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +42.12%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.01%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -8.84%.
Reported Earning Dates
ILMN is expected to report earnings on Feb 11, 2027.
PACB is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical Specialties (-2.30% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-2.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
PACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PACB has been loosely correlated with TXG. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then TXG could also see price increases.
| Ticker / NAME | Correlation To PACB | 1D Price Change % | ||
|---|---|---|---|---|
| PACB | 100% | +4.05% | ||
| TXG - PACB | 52% Loosely correlated | +5.94% | ||
| BFLY - PACB | 52% Loosely correlated | +4.23% | ||
| QSI - PACB | 49% Loosely correlated | +3.17% | ||
| MASS - PACB | 48% Loosely correlated | +4.51% | ||
| ILMN - PACB | 48% Loosely correlated | +5.13% | ||
More | ||||